LEXX Stock Analysis: Buy, Sell, or Hold?
LEXX - Lexaria Bioscience Corp. Common Stock
$10.54
-0.38 (-3.44%)
▼
5d:
+2.13%
30d:
+1785.51%
90d:
+1521.54%
WAIT
LOW Confidence
Analysis Updated: Aug 24, 2026 12:00 AM ET
Earnings: Jul 13, 2026
0d
Get Alerted When LEXX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR BETTER ENTRY: LEXX is 17.9% above its trading range ($8.94). While momentum could continue, risk/reward favors waiting for a pullback.
⏸️ WAIT FOR BETTER ENTRY: LEXX is 17.9% above its trading range ($8.94). While momentum could continue, risk/reward favors waiting for a pullback.
In-depth Analysis How we analyze
Valuation Analysis: LEXX is currently trading at $10.54, which is considered extended relative to its 30-day fair value range of $0.61 to $8.94.
Technical Outlook: Technically, LEXX is in a uptrend. Immediate support is located at $5.50, while resistance sits at $12.89. Short-term momentum is weak, with the stock down 3.4% recently.
Market Sentiment: LEXX scores 0/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $52.50 (+398.1%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, LEXX is in a uptrend. Immediate support is located at $5.50, while resistance sits at $12.89. Short-term momentum is weak, with the stock down 3.4% recently.
Market Sentiment: LEXX scores 0/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $52.50 (+398.1%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$0.61 -
$8.94
Company Quality Score
33/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
10.5%
All Signals
- BEARISH: Price significantly overextended (+17.9% above its trading range)
- BEARISH: Weak technical setup (0/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-3.4%)
- BULLISH: Trading 398.1% below Wall St target ($52.50)
- WARNING: Composite score 33/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$0.61 -
$8.94
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$5.50
Resistance Level
$12.89
Current Trend
Uptrend
Technical data as of
Aug 24, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-2.27
Wall Street Target
$52.50
(+398.1%)
Revenue Growth (YoY)
-88.5%
Share & Embed Analysis
Last updated: August 24, 2026 6:42 PM ET
Data refreshes hourly during market hours. Next update: 7:42 PM
Data refreshes hourly during market hours. Next update: 7:42 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is LEXX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
RARE
Ultragenyx |
STRONG BUY
20 analysts |
$55 | 62 BUY |
|
XENE
Xenon Pharmaceuticals Inc |
STRONG BUY
19 analysts |
$81 | 53 HOLD |
|
INSM
Insmed Inc |
STRONG BUY
21 analysts |
$200 | 34 SELL |
|
RCKT
Rocket Pharmaceuticals I… |
STRONG BUY
18 analysts |
$9 | 47 HOLD |
|
VKTX
Viking Therapeutics Inc |
STRONG BUY
19 analysts |
$92 | 43 HOLD |
